GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Cyclically Adjusted PS Ratio

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Cyclically Adjusted PS Ratio : (As of Jun. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pathfinder Cell Therapy Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Pathfinder Cell Therapy's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy Cyclically Adjusted PS Ratio Chart

Pathfinder Cell Therapy Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pathfinder Cell Therapy Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pathfinder Cell Therapy's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Pathfinder Cell Therapy's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pathfinder Cell Therapy's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's Cyclically Adjusted PS Ratio falls into.



Pathfinder Cell Therapy Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Pathfinder Cell Therapy's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2015 is calculated as:

For example, Pathfinder Cell Therapy's adjusted Revenue per Share data for the three months ended in Sep. 2015 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2015 (Change)*Current CPI (Sep. 2015)
=0/100.3915*100.3915
=0.000

Current CPI (Sep. 2015) = 100.3915.

Pathfinder Cell Therapy Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200512 0.000 83.032 0.000
200603 0.000 84.298 0.000
200606 0.000 85.606 0.000
200609 0.001 85.606 0.001
200612 0.001 85.142 0.001
200703 0.001 86.640 0.001
200706 0.000 87.906 0.000
200709 0.000 87.964 0.000
200712 0.000 88.616 0.000
200803 0.000 90.090 0.000
200806 0.001 92.320 0.001
200809 0.001 92.307 0.001
200812 0.001 88.697 0.001
200903 0.001 89.744 0.001
200906 0.001 91.003 0.001
200909 0.001 91.120 0.001
200912 0.001 91.111 0.001
201003 0.001 91.821 0.001
201006 0.001 91.962 0.001
201009 0.000 92.162 0.000
201012 0.000 92.474 0.000
201103 0.000 94.283 0.000
201106 0.000 95.235 0.000
201109 0.000 95.727 0.000
201112 0.000 95.213 0.000
201203 0.000 96.783 0.000
201206 0.000 96.819 0.000
201209 0.000 97.633 0.000
201212 0.000 96.871 0.000
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pathfinder Cell Therapy  (OTCPK:PFND) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Pathfinder Cell Therapy Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines